The purpose of this research is to test the effects of an herbal combination formulation on hair growth in women with self-perceived hair loss.The information from this study may help to better understand how certain herbal supplements can affect hair growth. This may lead to better understanding of the hair, hair loss and help develop naturally-based treatment regimens in the future.
The Effect of an Oral Herbal Combination Formulation on Hair Growth in Women With Self-perceived Hair Loss
Subject must be able to read and comprehend study procedures and consent forms.
Women with self-perceived hair loss as confirmed by the investigator.
Willing to maintain the same hairstyle, hair color, hair length and hair regimen throughout the study period. Subjects with color-treated hair will have the color treatment performed at the same time interval prior to each visit (if the color treatment was done 1 week prior to Visit 1, it should be repeated 1 week prior to Visit 2).
Willing to keep diet and exercise routine consistent throughout study
You CAN'T join if...
Subjects should be generally healthy and have no smoking history in the past one year.
Women who are pregnant, planning to become pregnant or breastfeeding
Those who are unable to discontinue medicated shampoos or topical scalp medications for two weeks prior to and during the study.
Those who are unable to discontinue supplements containing Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa for one month prior to starting the study
Those who have a known allergy to Eclipta alba, Emblica officinalis, Centella asiatica or Hibiscus sabdariffa
Use of hair regrowth products in the previous 6 months
Using or planned use of non-breathable wigs
Those with a history of hair transplantation procedure
Presence of other dermatological disorders causing alopecia
Chemotherapy, radiation therapy or laser therapy (of scalp) in the last 6 months
Light therapy in the past 3 months
Participants using hormonal birth control unless on a stable / unchanged regimen for at least 3 months.
Systemic treatment during the last 3 months before study inclusion that could interfere with the study medications (ie, minoxidil, corticosteroids, Aminexil, topical estrogens, ketoconazole, beta blocker, cimetidine, diazoxide, isotretinoin or vitamin A intake >10,000 IU/d)
Use of ocular prostaglandins for less than 4 months before first study visit